Detalhe da pesquisa
1.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Diabetes Obes Metab
; 25(12): 3453-3464, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37712754
2.
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Diabetes Obes Metab
; 25(12): 3465-3477, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37700627
3.
Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes.
Qual Life Res
; 32(12): 3359-3371, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491582
4.
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Diabetes Obes Metab
; 24(9): 1861-1868, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35589616
5.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Diabetes Obes Metab
; 24(12): 2373-2382, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876235
6.
Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.
Diabetes Obes Metab
; 21(12): 2660-2666, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392822
7.
Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Diabetes Res Clin Pract
; 212: 111717, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38777128
8.
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
Lancet
; 379(9833): 2270-8, 2012 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22683137
9.
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
Health Qual Life Outcomes
; 11: 217, 2013 Dec 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24369764
10.
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS).
BMC Psychiatry
; 13: 79, 2013 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23510483
11.
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Diabetes Ther
; 14(11): 1867-1887, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668888
12.
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
Diabetes Ther
; 14(11): 1833-1852, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526908
13.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
Diabetes Ther
; 12(7): 1929-1946, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097244
14.
Patient characteristics of insulin lispro 200 units/mL users in real world setting in Germany.
Curr Med Res Opin
; 36(10): 1611-1617, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32845743
15.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
Diabetes Ther
; 11(10): 2383-2399, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32880876
16.
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Diabetes Ther
; 8(1): 115-128, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28070733
17.
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
Diabetes Care
; 36(5): 1368-76, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23275363
18.
Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort.
Int J Methods Psychiatr Res
; 22(1): 46-58, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23526724
19.
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
Diabetes Ther
; 4(2): 285-308, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24018835
20.
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
Diabetes Metab Syndr Obes
; 6: 171-85, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23667315